NSRGY - Aimmune Therapeutics: A Bargain For A Potential Blockbuster Therapy
Investment Thesis
Earlier this year, Aimmune Therapeutics, Inc. (AIMT) unveiled Palforzia, the first and only FDA approved therapy to suppress the effects of peanut allergy. The lockdown measures hindered its market launch, and the company failed to realize sales to arrest the stock’s decline. Despite a rich portfolio of drugs addressing the food allergy, the sharp undervaluation of the stock has attracted acquirers such as Nestle, which recently bid for the company with a premium of ~174% to the pre-merger share price.
With European approval for Palforzia ahead, the Swiss consumer giant can